This $697,590 federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) to evaluate B-T cell cross-talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The grant, with a performance period from July 1, 2024 to June 30, 2027, aims to advance scientific understanding of how interactions between B and T cells in the tumor microenvironment impact melanoma progression and response to immunotherapies. As a National Cancer Institute-designated comprehensive cancer center, Moffitt Cancer Center has extensive expertise in cancer biology, immunology, and translational research to support this project. The findings from this federally-funded study may contribute to the development of more effective treatments for melanoma patients.
Generated 4/8/25, 3:28 AM